<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04253223</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00102920</org_study_id>
    <nct_id>NCT04253223</nct_id>
  </id_info>
  <brief_title>A Study to Determine Safety and Efficacy of (REMD-477) in Controlling Hyperglycemia Due to Copanlisib</brief_title>
  <official_title>A Phase I/Ib Pilot Study to Determine the Safety and Efficacy of a Human Anti-glucagon Receptor Antibody (REMD-477) in Controlling Severe Hyperglycemia Due to Copanlisib in Patients With Relapsed or Refractory Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      REMD-477 is a human anti-glucagon receptor antibody. Its proposed mechanism of action in
      controlling hyperglycemia is by blocking glucagon receptor (GCGR) signaling. In this way, it
      increases hepatic glucose uptake, decreases hepatic glycogenolysis and gluconeogenesis,
      increases glycogen synthesis, and ultimately decreases blood glucose levels. This protocol
      will test the hypotheses that REMD-477 is safe and tolerable in patients with severe
      hyperglycemia on copanlisib and that it decreases the risk of severe hyperglycemia in
      patients receiving copanlisib for relapsed refractory lymphoma
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 7, 2020</start_date>
  <completion_date type="Anticipated">March 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 15, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>22 days</time_frame>
    <description>Evaluate the safety of REMD-477 in patients with hyperglycemia due to a PI3 kinase inhibitor</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serious Adverse Events</measure>
    <time_frame>22 days</time_frame>
    <description>Evaluate the safety of REMD-477 in patients with hyperglycemia due to a PI3 kinase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Liver Function Tests (LFT) units per liter (u/L)</measure>
    <time_frame>22 days</time_frame>
    <description>Evaluate the safety of REMD-477 in patients with hyperglycemia due to a PI3 kinase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood Glucose measurements</measure>
    <time_frame>22 days</time_frame>
    <description>Evaluate the safety of REMD-477 in patients with hyperglycemia due to a PI3 kinase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pulse beats per minute</measure>
    <time_frame>22 days</time_frame>
    <description>Evaluate the safety of REMD-477 in patients with hyperglycemia due to a PI3 kinase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>breathing Rate breaths per minute</measure>
    <time_frame>22 days</time_frame>
    <description>Evaluate the safety of REMD-477 in patients with hyperglycemia due to a PI3 kinase</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fasting Glucose levels</measure>
    <time_frame>22 days</time_frame>
    <description>Determine efficacy of REMD-477 in preventing copanlisib induced hyperglycemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin levels</measure>
    <time_frame>22 days</time_frame>
    <description>Determine efficacy of REMD-477 in preventing copanlisib induced hyperglycemia</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Hyperglycemia Drug Induced</condition>
  <arm_group>
    <arm_group_label>REMD-477</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>REMD-477 (human IgG2 anti-glucagon receptor antibody) will be administered as a subcutaneous injection for three weekly doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>REMD-477</intervention_name>
    <description>REMD-477 will be administered as a subcutaneous injection for three weekly doses</description>
    <arm_group_label>REMD-477</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 or older

          -  Relapsed or refractory lymphoma (Grade 1, 2, 3A)

          -  Received 2 or more prior lines of systemic therapy for lymphoma

          -  Experienced glucose &gt;250 mg/dL after copanlisib infusion for treatment of lymphoma

        Exclusion Criteria:

          -  Evidence of histologic transformation

          -  Follicular Lymphoma Grade 3B

          -  Active CNS involvement by malignancy

          -  Elevated AST or ALT &gt; 5x ULN at Screening

          -  Unmanageable sensitivity to mammalian-derived drug preparations, or to humanized or
             human antibodies; managed sensitivities to agents such as obinutuzumab or rituximab or
             similar agents are not exclusionary

          -  History of drug or alcohol abuse within the last 6 months

          -  History or family history of pancreatic neuroendocrine tumors or multiple endocrine
             neoplasia

          -  History or family history of pheochromocytoma

          -  Other gastrointestinal, cardiac, renal and CNS (i.e. hypoglycemia unawareness)
             conditions specific to diabetes that would pose additional risk to subject's safety or
             interfere with the study evaluation, procedures or completion in the opinion of the
             treating physician.

          -  Female subject is pregnant or breastfeeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jie Wang, MD</last_name>
    <phone>919 668 1000</phone>
    <email>jie.wang416@duke.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lauren Galentine</last_name>
    <phone>919-668-5579</phone>
    <email>lauren.galentine@duke.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jie Wang, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Jie Wang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>January 28, 2020</study_first_submitted>
  <study_first_submitted_qc>January 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>May 6, 2020</last_update_submitted>
  <last_update_submitted_qc>May 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Duke University</investigator_affiliation>
    <investigator_full_name>Herbert Lyerly</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>hyperglycemia</keyword>
  <keyword>lymphoma</keyword>
  <keyword>anti-glucagon receptor antibody</keyword>
  <keyword>glucagon receptor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>REMD-477</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

